Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. DARE

(DARE)

0.00

0.00 (0.00%)

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Daré Bioscience, Inc.

CountryUnited States
IndustryBiotechnology
SectorHealthcare
IPO DateN/A
CEOSabrina Johnson

About the company

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

Key Executives

NamePosition
Dr. David Friend Ph.D.Chief Scientific Officer
Jennifer KiangVice President of Corporate Affairs & Development
Mr. Mark WaltersVice President of Operations
Ms. MarDee J. Haring-LaytonChief Accounting Officer
Ms. Sabrina Martucci JohnsonCEO, President, Principal Financial Officer, Secretary & Director

Daré Bioscience, Inc.

CountryUnited States
IndustryBiotechnology
SectorHealthcare
IPO DateN/A
CEOSabrina Johnson

Contact Details

Address:3655 Nobel Drive, Suite 260, San Diego, California 92122, United States
Phone:858 926 7655
Website:https://darebioscience.com

Stock Details

Latest SEC Filings

DateTypeDocument
2026-03-178-Kform8-k.htm
2026-03-098-Kform8-k.htm
2026-03-028-Kform8-k.htm
2026-01-298-Kform8-k.htm
2026-01-07253G1form253g1.htm
2026-01-068-Kform8-k.htm
2025-12-291-A/A
2025-12-018-Kform8-k.htm
2025-11-251-A
2025-11-1310-Qdare-20250930.htm
Ticker Symbol:DARE
Exchange:NASDAQ
Fiscal Year:January - December
Reporting Currency:USD
CIK Code:0001401914
CUSIP Number:23666P101
ISIN Number:US23666P2002
Employer ID:20-4139823
SIC Code:2834